The publication reported body-weight and glycemic endpoints that were qualitatively consistent with REDEFINE 1, with the combination arm favored over placebo on the reported measures
In contrast, limited weight loss or persistent appetite should prompt assessment of medication exposure, dose escalation, gastrointestinal tolerability, adherence, treatment interruption, concomitant medications, dietary compensation, and behavioural drivers of eating, consistent with evidence that early response may help identify patients more likely to achieve clinically meaningful longer-term weight loss (93)
Aunque muchos pacientes experimentan adaptacin con el tiempo, algunos requieren intervencin farmacolgica para mantener la funcin intestinal normal y la calidad de vida durante el tratamiento
GLP-1 weight loss is strong enough that gabapentin-related weight gain is usually a minor factor